Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States-Reference-Cited by-同舟云学术

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States

Published:2018-09 Issue:9 Volume:18 Page:590-596
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Mesa Ruben,Boccia Ralph V.,Grunwald Michael R.^ORCID,Oh Stephen T.,Colucci Philomena,Paranagama Dilan,Parasuraman Shreekant,Stein Brady L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference16 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

2. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study;Hultcrantz;J Clin Oncol,2012

3. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs;Emanuel;J Clin Oncol,2012

4. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms;Johansson;Leuk Lymphoma,2012

5. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey;Mesa;BMC Cancer,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. The assessment of health-related quality of life in patients with polycythemia vera;Medicine;2024-07-26

3. Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG‐300), a hepcidin mimetic, in healthy volunteers: A double‐blind first‐in‐human study;European Journal of Haematology;2024-05-24

4. Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera;British Journal of Clinical Pharmacology;2024-03-19

5. Real-World Clinical Characterisation of Polycythaemia Vera Patients from a Prospective Registry in Portugal: Is Resistance to Hydroxyurea a Reality?;Hematology Reports;2023-09-13